Taihe Pharma

Taihe Biopharma is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of innovative cell therapies for cancer. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) technologies to treat both hematological malignancies and solid tumors. Their lead candidate, TAI-19, is a CD19-targeted CAR-T therapy currently in Phase 2 clinical trials for various B-cell malignancies. The pipeline also includes TAI-BCMA for multiple myeloma and TAI-GPC3 for hepatocellular carcinoma, reflecting a commitment to addressing unmet needs in oncology. Taihe Biopharma utilizes proprietary platforms to enhance the safety, efficacy, and persistence of engineered T-cells. The company aims to become a leader in the global cell therapy market through rigorous clinical development and strategic collaborations.